logo-loader
NASDAQ:KZIA

Kazia Therapeutics Ltd

Receive alerts
Market:
NASDAQ
Price
5.65 USD
Day Change
2.91%
Market Cap:
$87.85 m
52 weeks high
17.30
52 weeks low
4.91

In brief

Kazia Therapeutics Ltd (NASDAQ:KZIA) is an innovative oncology-focused biotechnology company based in Sydney.

The company’s product pipeline includes two clinical-stage drug development candidates and Kazia is also working to develop therapies across a range of oncology indications.

Kazia’s lead program is paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K/AK/mTOR pathway, which is being developed to treat glioblastoma, the most common and aggressive form of primary brain cancer in adults.